Vodafone Group Plc has announced that Simon Dingemans will be appointed as a non-executive director with effect from 1 January 2025. He will sit on the audit & risk committee.

Dingemans currently serves as chair of Genomics, a pioneering healthcare company, and as a non-executive director of WPP plc, the FTSE 100 global creative transformation company, where he is a member of the audit committee. He is also the independent chair of Calastone, a portfolio company of The Carlyle Group and a global funds network connecting some of the world’s leading financial institutions.

Previously, Dingemans served as chair of the Financial Reporting Council, stepping down in 2020 after less than a year in the role.

In his executive career, Dingemans was group CFO of GSK plc, the global healthcare group, from 2011 to 2019, where he played a key role in reshaping the organisation into two distinct biopharma and consumer health care businesses.

Prior to GSK, Dingemans worked in investment banking for more than 25 years, at SG Warburg and then Goldman Sachs, where he was a partner and head of UK investment banking, as well as a leader in the European Mergers business.

Vodafone’s chair, Jean-François van Boxmeer, said: “I am delighted to welcome Simon to Vodafone’s Board. He is a highly regarded business leader with extensive financial, operational and strategic experience. Simon’s expertise will be a valuable addition to the Board as we continue to drive the execution of Vodafone’s strategy to achieve our commercial priorities and deliver long-term value to our shareholders.”